However, in another randomised trial, Callens et al. reported that a longer duration of treatment (4 months) of insulin detemir (40 IU) had no significant effects on the cognitive functions of individuals diagnosed with mild to moderate AD or MCI, highlighting the risk for application of long-acting insulin in desensitizing the insulin receptors [110]. The gene discussed is INSR; the disease is Alzheimer disease.